Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide: twenty years later

J D Hainsworth1, F A Greco

  • 1Sarah Cannon (Minnie Pearl) Cancer Center, Centennial Medical Center, Nashville, TN, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

International journal of clinical oncology·2013
Same author

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Cancer treatment reviews·2008
Same author

Diagnostic and therapeutic management of cancer of an unknown primary.

European journal of cancer (Oxford, England : 1990)·2003
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Etoposide is a crucial chemotherapy drug for germ cell tumors and small-cell lung cancer. Ongoing research aims to optimize its use and expand its applications in various cancers and drug combinations.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Etoposide has been a cornerstone in clinical oncology for two decades.
  • Its established efficacy in germ cell tumors and small-cell lung cancer continues.
  • Increasing use is observed in non-Hodgkin's lymphoma and high-dose chemotherapy regimens.

Purpose of the Study:

  • To review the current and future role of etoposide in cancer treatment.
  • To highlight ongoing research into optimizing etoposide's dose and schedule.
  • To explore novel therapeutic combinations and strategies to overcome resistance.

Main Methods:

  • Review of clinical data and ongoing research in etoposide therapy.
  • Analysis of etoposide's established applications and potential new uses.
  • Discussion of future directions in etoposide-based cancer treatment.

Related Experiment Videos

Main Results:

  • Etoposide remains vital for specific cancers and its use is expanding.
  • Research is actively refining etoposide dosing and scheduling for improved outcomes.
  • Potential for new combination therapies, including with topoisomerase I inhibitors, is promising.

Conclusions:

  • Etoposide's importance in oncology is set to grow over the next decade.
  • Further research will likely enhance its clinical activity and broaden its application.
  • Development of strategies to combat drug resistance will be key to future success.